Identification
- Summary
Ioxitalamic acid is a contrast agent used for CT scans of the abdomen and pelvis.
- Generic Name
- Ioxitalamic acid
- DrugBank Accession Number
- DB13444
- Background
Ioxitalamate is an ionic iodinated contrast medium.1 It is a first-generation contrast media formed by an ionic monomer with a high osmolarity of 1500-1800 mOsm/kg.2 Ioxitalamic acid in the salt forms of sodium and meglumine was developed by Liebel-Flarshem Canada Inc and approved by Health Canada in 1995. Until the last review in 2015, this drug is still available in the market.7
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Ioxitalamic acid (DB13444)
- Weight
- Average: 643.942
Monoisotopic: 643.78021 - Chemical Formula
- C12H11I3N2O5
- Synonyms
- Acide ioxitalamique
- Acido ioxitalamico
- Acidum ioxitalamicum
- Ioxitalamic acid
- External IDs
- AG 58107
- AG-58107
Pharmacology
- Indication
Ioxitalamate in both of its available forms is indicated for exploration of the digestive tract by tomodensitometry or by regular gastroduodenal radiography. Its use is restrained to the cases in which the administration of barium sulfate is not recommended or contraindicated.9 The intravascular administration of ioxitalamate is contraindicated as it may present significant side effects.8
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Ioxitalamate presents a very large osmolality which is related to the presence of renal toxicity, vasodilatation, bradycardia and pulmonary hypertension. This large osmolality allows ioxitalamate to move slowly in the bowel allowing for analysis for later follow excretion in the feces.3
- Mechanism of action
Ioxitalamate acts as a bowel opacifier which facilitates the interpretation of the anatomy and differentiation of bowel loops from soft tissue masses.8
- Absorption
When administered ioxitalamate is not absorbed in the GI tract. In the case of presence of an intestinal perforation, ioxitalamate is completely absorbed.9 When administered intravascularly, ioxitalamate is rapidly distributed in the interstitial space and intravascular compartment.10
- Volume of distribution
The volume of distribution of ioxitalamate is 194 ml/kg.10
- Protein binding
Iodinated monomeric contrast agents are rarely bound to plasma proteins and when they bind, usually the association is very weak.4 When bound, it only represents from 0 to 27% of the ioxitalamate administered dose.5
- Metabolism
The rapid clearance suggests that ioxitalamate is not metabolized in the body.6
- Route of elimination
As ioxitalamate is not absorbed in the normal intestine, the elimination route of this compound is entirely performed by the feces. When absorbed due to the presence of an intestinal perforation, ioxitalamate presents a rapid renal elimination.9 when ioxitalamate is administered intravascularly, it is eliminated unchanged mainly via renal excretion through glomerular filtration without reabsorption or tubular secretion. In the cases of renal failure, the elimination is mainly performed in the biliary, salivary, sudoral and colic route.10
- Half-life
The elimination half-life of ioxitalamate is 1.1 hours.10
- Clearance
The total clearance rate of ioxitalamate is 120 ml/min.10
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Ioxitalamate is reported to induce acute kidney injury.2 Preclinical studies showed that it does not present a teratogenic potential as well as a lack of effect on fertility.9 Ioxitalamate overdose may increase the risk of nephropathy and cardiovascular disorders.8
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Meglumine ioxitalamate 5791GC9HSW 29288-99-1 IFTFXKNYTWAOGK-WZTVWXICSA-N Sodium ioxitalamate 8P8Y8ZXJ8Y 33954-26-6 PZTAFRMXSAAHMQ-UHFFFAOYSA-M - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image TELEBRIX 35 FLAKON, 100 ML Meglumine ioxitalamate (65 g/100ml) + Sodium ioxitalamate (9.66 g/100ml) GUERBET İLAÇ TIBBİ MALZEME VE CİHAZLAR SAN. VE TİC. A.Ş. 1996-12-27 2021-09-07 Turkey 
TELEBRIX 35 FLAKON, 100 ML Meglumine ioxitalamate (65 g/100ml) + Sodium ioxitalamate (9.66 g/100ml) GUERBET İLAÇ TIBBİ MALZEME VE CİHAZLAR SAN. VE TİC. A.Ş. 1996-12-27 2021-09-07 Turkey Telebrix 38 Oral Meglumine ioxitalamate (513 mg / mL) + Sodium ioxitalamate (255 mg / mL) Solution Oral Liebel Flarsheim Company Llc 1995-12-31 2020-08-07 Canada 
Telebrix 38 Oral Meglumine ioxitalamate (513 mg / mL) + Sodium ioxitalamate (255 mg / mL) Solution Oral Liebel Flarsheim Company Llc 1995-12-31 2020-08-07 Canada เทเลบริกส์ 35 Meglumine ioxitalamate (65.09 G/100ML) + Sodium ioxitalamate (9.66 G/100ML) Solution Oral บริษัท แปซิฟิค เฮลธ์แคร์ (ไทยแลนด์) จำกัด 1989-12-29 Not applicable Thailand 
Categories
- ATC Codes
- V08AA05 — Ioxitalamic acid
- Drug Categories
- Acids, Carbocyclic
- Alcohols
- Amino Sugars
- Benzene Derivatives
- Benzoates
- Carbohydrates
- Compounds used in a research, industrial, or household setting
- Contrast Media
- Diagnostic Uses of Chemicals
- Hexosamines
- Iodobenzoates
- Sugar Alcohols
- Triiodobenzoic Acids
- Watersoluble, Nephrotropic, High Osmolar X-Ray Contrast Media
- X-Ray Contrast Media, Iodinated
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as halobenzoic acids. These are benzoic acids carrying a halogen atom on the benzene ring.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Halobenzoic acids
- Alternative Parents
- 2-halobenzoic acids / 4-halobenzoic acids / Benzoic acids / 1-carboxy-2-haloaromatic compounds / Benzoyl derivatives / Iodobenzenes / Aryl iodides / Vinylogous halides / Propargyl-type 1,3-dipolar organic compounds / Alkanolamines show 7 more
- Substituents
- 1-carboxy-2-haloaromatic compound / 2-halobenzoic acid / 2-halobenzoic acid or derivatives / 4-halobenzoic acid / 4-halobenzoic acid or derivatives / Alcohol / Alkanolamine / Aromatic homomonocyclic compound / Aryl halide / Aryl iodide show 23 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- organoiodine compound, dicarboxylic acid monoamide, acetamides, benzoic acids (CHEBI:83517)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 967RDI7Z6K
- CAS number
- 28179-44-4
- InChI Key
- OLAOYPRJVHUHCF-UHFFFAOYSA-N
- InChI
- InChI=1S/C12H11I3N2O5/c1-4(19)17-10-8(14)5(11(20)16-2-3-18)7(13)6(9(10)15)12(21)22/h18H,2-3H2,1H3,(H,16,20)(H,17,19)(H,21,22)
- IUPAC Name
- 3-acetamido-5-[(2-hydroxyethyl)carbamoyl]-2,4,6-triiodobenzoic acid
- SMILES
- CC(=O)NC1=C(I)C(C(O)=O)=C(I)C(C(=O)NCCO)=C1I
References
- General References
- Kim KH, Kim YS, Kuh SU, Park HS, Park JY, Chin DK, Kim KS, Cho YE: Time- and dose-dependent cytotoxicities of ioxitalamate and indigocarmine in human nucleus pulposus cells. Spine J. 2013 May;13(5):564-71. doi: 10.1016/j.spinee.2013.01.019. Epub 2013 Feb 11. [Article]
- Hsu SP, Tsai TJ, Chien CT: Ioxitalamate induces renal tubular apoptosis via activation of renal efferent nerve-mediated adrenergic signaling, renin activity, and reactive oxygen species production in rats. Toxicol Sci. 2010 Mar;114(1):149-58. doi: 10.1093/toxsci/kfp290. Epub 2009 Nov 26. [Article]
- Lusic H, Grinstaff MW: X-ray-computed tomography contrast agents. Chem Rev. 2013 Mar 13;113(3):1641-66. doi: 10.1021/cr200358s. Epub 2012 Dec 5. [Article]
- Buthiau D. and Khayat D. (1995). CT and MRI in oncology. Springer-Verlag. [ISBN:978-3-642-46844-5]
- Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
- Coyne C. (2006). Comparative diagnostics pharmacology. Blackwell publishing. [ISBN:978-0-8138-1753-8]
- Health Canada [Link]
- Health Canada label [File]
- Telebrix Gastro monograph [File]
- Telebrix summary of product [File]
- External Links
- KEGG Drug
- D07418
- ChemSpider
- 31782
- ChEBI
- 83517
- ChEMBL
- CHEMBL2107239
- ZINC
- ZINC000004216615
- Wikipedia
- Ioxitalamic_acid
- MSDS
- Download (127 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Intravascular 66 g/100ml Injection, solution Intravascular 66.03 g Solution Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 349 ºC 'MSDS' water solubility Soluble Product Characteristics - Predicted Properties
Property Value Source Water Solubility 0.265 mg/mL ALOGPS logP 1.36 ALOGPS logP 2.04 Chemaxon logS -3.4 ALOGPS pKa (Strongest Acidic) 2.13 Chemaxon pKa (Strongest Basic) -1.8 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 115.73 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 108.53 m3·mol-1 Chemaxon Polarizability 41.6 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 188.41158 predictedDeepCCS 1.0 (2019) [M+H]+ 191.25664 predictedDeepCCS 1.0 (2019) [M+Na]+ 199.36772 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:42 / Updated at February 03, 2022 06:26